Shots:

• The US FDA has granted 510(k) clearance for the ScleroSafe platform for efficient, non-thermal, non-tumescent (NT-NT) treatment and management of varicosities in superficial veins in the legs
• VVT’s unique, inverse-action dual syringe injects a sclerosing substance into the vein through one syringe while simultaneously aspirating blood through the second syringe. All within a single motion and with single-hand operation
• The syringe is compatible with both foam and liquid ECA substances. Additionally, ScleroSafe was approved in multiple regions, incl. EU, Australia, Southeast Asia, and South America

Ref: prnewswire | Image: VVT Medical